Stock Movers

iHeartPodcasts
  • 0.0 (0)
  • BUSINESS NEWS
  • UPDATED DAILY

Listen for five-minute conversations on today's biggest winners and losers in the stock market.  Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

  1. 30 MIN AGO

    Nike Slips, Airlines Surge, Apellis Pharma Soars

    On this episode of Stock Movers:- Nike (NKE) shares slipped despite reporting better-than-expected sales on concerns that the war in Iran could exacerbate weakness in the region that includes Europe and the Middle East and disrupt the sportswear company’s turnaround. Sales were $11.3 billion in the company’s fiscal third quarter, surpassing the average of estimates compiled by Bloomberg but flat from a year earlier. While performance in China improved, the Converse brand remained a problem area and the EMEA region, which also includes Africa, missed estimates.- Airlines climb as much as: United +8.6%, Delta +6.7%, American +6.1%. The S&P Supercomposite Airlines Industry Index jumps as much as 6.6%, the most since Feb. 6. Jet fuel prices have soared during the war, prompting warnings from across Wall Street about the financial impact on carriers and pushing the airlines index into a bear market- Biogen has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, more than double its closing price on Monday, Biogen said in a statement, confirming a Bloomberg News report. Apellis’ (APLS) stock had declined 32% so far this year through Monday’s close. Apellis shares soared 135% to $40.23 on Tuesday in New York, their largest jump ever. Biogen shares closed down 2.3%. See omnystudio.com/listener for privacy information.

    3 min

  2. 1 HR AGO

    Closing Bell: Marvell Surges on Nvidia Deal, Delta Rises, McCormick Sinks

    On this episode of Stock Movers:Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Katie Greifeld, Carol Massar and Tim Stenovec.- Marvell Technology (MRVL) shares soared in trading on Tuesday on news that Nvidia will take a $2 billion stake in it. Nvidia, which has made several billion-dollar investments in firms across the artificial intelligence supply chain in recent years, and Marvell also agreed to collaborate on the development of silicon photonics, which use light instead of traditional copper wiring to move data faster and more efficiently. And the companies will work together on ways to better leverage telecommunications networks for AI computing, according to a statement issued Tuesday.- Delta Airlines (DAL) will use Amazon.com Inc.’s satellites to deliver in-flight Wi-Fi service, a big win for the e-commerce giant’s space business as it vies with Elon Musk’s Starlink for aviation customers. Delta agreed to install the Amazon Leo internet service on 500 aircraft starting in 2028, enabling faster and more reliable internet to support streaming video and messaging, according to a Tuesday announcement from the airline. Shares of Delta rallied.- McCormick (MKC) shares slipped in trading on Tuesday as the spice company agreed to combine with Unilever’s Foods business in a deal valuing Unilever Foods at about $44.8 billion and at enterprise value for McCormick of about $21.0 billion. See omnystudio.com/listener for privacy information.

    5 min

  3. 3 HR AGO

    Constellation Energy Drops, Marvell Rallies on Nvidia Investment, Unilever Slides

    Today's biggest winners and losers in the stock market.On this episode of Stock Movers: - Constellation Energy (CEG) shares fell as much as 9.3% after it gave an full-year earnings per share guidance that missed the average analyst estimate at the midpoint, and failed to advance details on data-center deals.- Marvell Technology (MRVL) shares jumped as much as 11% in trading on Tuesday on news that Nvidia (NVDA) is taking a $2 billion stake in it. Nvidia, which has made several billion-dollar investments in firms across the artificial intelligence supply chain in recent years, and Marvell also agreed to collaborate on the development of silicon photonics, which use light instead of traditional copper wiring to move data faster and more efficiently. And the companies will work together on ways to better leverage telecommunications networks for AI computing, according to a statement issued Tuesday.- Unilever (ULVR) shares fall as much as 7.3% in London to the lowest level since April 2024 after the Anglo-Dutch company confirmed a $44.8 billion deal to combine its food business with spice maker McCormick. Analysts at RBC Capital Markets said they are unimpressed by the deal. McCormick shares fell as much as 10% to the lowest since November 2017. See omnystudio.com/listener for privacy information.

    4 min

  4. 7 HR AGO

    Constellation Energy Falls, McCormick Slides, Apellis Pharmaceuticals Gains

    On this episode of Stock Movers:- Constellation Energy (CEG) shares fall after it gave an full-year earnings per share guidance that missed the average analyst estimate at the midpoint.- McCormick (MKC) shares decline. Unilever Plc agreed to combine its food business with McCormick & Co. in a $44.8 billion deal that will create a global seasonings, sauces and condiments company. Under the agreement, McCormick will pay Unilever $15.7 billion and the equivalent of $29.1 billion McCormick shares for most of Unilever’s food business, leaving Unilever and its shareholders with 65% of the combined entity.- Apellis Pharmaceuticals (APLS) shares gain after Biogen agreed to acquire Apellis for $5.6 billion, expanding its treatments in immunology and rare diseases. The acquisition will give Biogen two approved drugs, Syfovre and Empaveli, which treat immune disorders and rare diseases, including a leading cause of blindness and rare kidney diseases. See omnystudio.com/listener for privacy information.

    2 min

  5. 8 HR AGO

    Eli Lilly Gains, McCormick Rises, Allbirds Soars on American Exchange Deal

    On this episode of Stock Movers:- Eli Lilly (LLY) shares gained. The company agreed to buy sleep drug maker Centessa Pharmaceuticals Plc in a deal worth up to $7.8 billion, a sign the weight-loss medication giant is looking to bulk up its treatment pipeline for other conditions.- McCormick (MKC) shares rise. Unilever Plc agreed to combine its food business with spice maker McCormick & Co. in a $44.8 billion deal that will create a global seasonings, sauces and condiments company. Under the agreement, McCormick will pay the Anglo-Dutch company $15.7 billion and the equivalent of $29.1 billion McCormick shares for most of Unilever’s food business.- Allbirds (BIRD) shares soar. American Exchange Group has agreed to buy all of the assets and intellectual property of once-buzzy footwear brand Allbirds Inc. for $39 million. The shoemaker said the deal, which is expected to close in the second quarter, still needs shareholder approval. A distribution of net proceeds to stockholders is expected in the third quarter. See omnystudio.com/listener for privacy information.

    4 min

  6. 9 HR AGO

    Biogen to Buy Apellis; Lilly to Buy Sleep Drug Maker; Nvidia Invests $2 Billion in Marvell

    Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions. The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday. Apellis’ stock has declined 32% so far this year. - Eli Lilly (LLY) agreed to buy sleep drug maker Centessa Pharmaceuticals Plc in a deal worth up to $7.8 billion, a sign the weight-loss medication giant is looking to bulk up its treatment pipeline for other conditions.Lilly will pay $38 a share for Centessa plus a further $9 a share if three milestone targets are met, according to a statement Tuesday. The total represents a 70% premium to Monday’s close. The upfront payment represents an equity value of about $6.3 billion, with potential additional payments of about $1.5 billion. - Nvidia (NVDA) said it has invested $2 billion in Marvell Technology (MRVL) as part of an agreement to collaborate on silicon photonics technology, an effort to make AI services more affordable amid historic investments in the new technology. See omnystudio.com/listener for privacy information.

    4 min

  7. 11 HR AGO

    Lilly to Buy Centessa Pharmaceuticals; Biogen to Buy Apellis; Unilever Foods Exit

    Today's biggest winners and losers in the stock market.On this episode of Stock Movers:- Lilly (LLY) to buy Centessa Pharmaceuticals for $38/share in cash plus one non-transferrable contingent value right that entitles the holder to get up to an aggregate of $9 subject to the achievement of three milestones.- Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday. Apellis’ stock has declined 32% so far this year.- Unilever (ULVR) said talks to sell most of its food business to McCormick (MKC) are advanced and a final deal could be announced later on Tuesday in a historic move that will transform both companies.The Anglo-Dutch maker of Hellmann’s mayonnaise will offload most of its food unit, excluding some parts like its operations in India, for $15.7 billion cash upfront and the rest in McCormick equity, according to a statement Tuesday. See omnystudio.com/listener for privacy information.

    4 min

  8. 13 HR AGO

    LVMH Falls, Future Slumps, Dermapharm Drops

    On this episode of Stock Movers:- LVMH, SAP, and Novo Nordisk have slumped by about 30% so far this year, making up about 53% of the total market capitalization shed by constituents of the Stoxx Europe 600 index.- Future slumps as much as 30%, to the lowest since October 2017, after what JPMorgan describes as a weak first-half trading update, showing impact from pressure on high-margin programmatic advertising and e-commerce revenue, and pay-per-click cost inflation.- Dermapharm shares fall 4.8% after the company announced full year results. Dermapharm forecast adjusted Ebitda for 2026 of EU331 million to EU341 million. See omnystudio.com/listener for privacy information.

    4 min
See All (2k)

Trailer

Hosts & Guests

About

Listen for five-minute conversations on today's biggest winners and losers in the stock market.  Subscribe for analysis on the companies making news in global equity markets. Episodes are published throughout the day to track stock moves from New York, London, Frankfurt and Paris. Join us for investment news covering technology, energy, finance, health care, communications, industrials, utilities, consumer staples, materials, real estate and more.

Information

  • Creator
    iHeartPodcasts
  • Years Active
    2025 - 2026
  • Episodes
    2k
  • Rating
    Clean
  • Copyright
    2026 iHeartMedia, Inc. © Any use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from iHeartMedia
  • Show Website
    Stock Movers

You Might Also Like